利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

964 条记录 (耗时 0.037 秒)

    GLUCOSE DERIVATIVES AND ANTICANCER AGENT USING SAME
    1.
    发明公开
    GLUCOSE DERIVATIVES AND ANTICANCER AGENT USING SAME 审中-公开

    公开(公告)号：US20240327450A1

    公开(公告)日：2024-10-03

    申请号：US18698654

    申请日：2022-10-03

    申请人： ORBIO CORPORATION

    发明人： Eiichi YAMAGUCHI ,  Katsuya YAMADA ,  Koki ONO ,  Kota TANAKA ,  Hideki IIJIMA

    IPC分类号： C07H23/00 ,  A61K31/7135 ,  A61P35/00

    CPC分类号： C07H23/00 ,  A61K31/7135 ,  A61P35/00

    摘要： Provided are novel glucose derivatives and an anticancer agent using the same. The glucose derivatives according to the present invention consist of an L-glucose derivative represented by general formula (1) and a D-glucose derivative represented by general formula (2). In formula (1): XL2 represents an —SAuRL2 group; and XL1, XL3, XL4 and XL5 independently represent an —ORL1 group, an —NH2 group or a fluorine atom. RL2 represents a ligand, and RL1 represents a hydrogen atom or an organic group. In formula (2): XD2 represents an —SAuRD2 group; and XD1, XD3, XD4 and XD5 independently represent an —ORD1 group, an —NH2 group or a fluorine atom. RD2 represents a ligand, and RD1 represents a hydrogen atom or an organic group. The anticancer agent according to the present invention comprises at least one of the aforesaid glucose derivatives.

    CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME
    3.
    发明公开
    CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME 审中-公开

    公开(公告)号：US20240262859A1

    公开(公告)日：2024-08-08

    申请号：US18566013

    申请日：2022-06-02

    申请人： TOKYO UNIVERSITY OF SCIENCE FOUNDATION

    发明人： Takeshi Wada ,  Kazuki Sato ,  Yuhei Takahashi

    IPC分类号： C07H23/00 ,  C07H1/00

    CPC分类号： C07H23/00 ,  C07H1/00

    摘要： A novel nucleic acid oligomer and a method for producing the same. The nucleic acid oligomer includes a nucleotide unit represented by general formula (1) and a nucleotide unit represented by general formula (2), and optionally includes a nucleotide unit represented by general formula (3). In general formulas (1), (2), and (3): R1 represents a hydrogen atom, a hydroxyl group, an alkoxy group, an alkenyloxy group, an acyloxy group, a trialkylsilyloxy group, an alkoxyalkoxy group, a haloalkoxyalkoxy group, or a halogenyl group, and R2 represents a hydrogen atom, or R1 and R2 bond together to form a five- or more-membered ring optionally having a substituent and optionally having a hetero atom; Bs represents a nucleobase selected from the group consisting of adenine, guanine, cytosine, 5-methylcytosine, thymine, and uracil, the nucleobase optionally having a nucleobase protecting group; and X+ represents a counter cation

    Methods and compositions for administration of iron
    9.
    发明授权
    Methods and compositions for administration of iron 有权

    公开(公告)号：US11364260B2

    公开(公告)日：2022-06-21

    申请号：US16825337

    申请日：2020-03-20

    申请人： American Regent, Inc.

    发明人： Mary Jane Helenek ,  Marc L. Tokars ,  Richard P. Lawrence

    IPC分类号： A61K31/7135 ,  A61K31/715 ,  A61K31/721 ,  C07H23/00

    摘要： The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

    Methods and compositions for administration of iron
    10.
    发明授权
    Methods and compositions for administration of iron 有权

    公开(公告)号：US11344568B2

    公开(公告)日：2022-05-31

    申请号：US16825121

    申请日：2020-03-20

    申请人： American Regent, Inc.

    发明人： Mary Jane Helenek ,  Marc L. Tokars ,  Richard P. Lawrence

    IPC分类号： A61K31/7135 ,  A61K31/715 ,  A61K31/721 ,  C07H23/00

    摘要： The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.